“Novel NEK2 signaling pathways in myeloma progression ”
06/01/20 – 05/31/25
US Department of Defense – W81XWH1910500
“CD24 Tumor-Initiating Cell as a Novel Therapeutic Target in Myeloma ”
04/15/20 – 11/14/23
Leukemia & Lymphoma Society – Advance Account
“Clinical Investigation of CD38+/Light chain+/CD24+ as Putative Multiple Myeloma Stem Celll Markers”
01/03/20 – 01/02/21
NIH/Nat. Cancer Institute – 7R01CA151354
“Biological Validation of Candidate Myeloma Driver Genes ”
01/01/20 – 06/30/23
Gao M, Bai H, Jethava Y, [et al., including Zhan F]. CD24 Is a Phenotypic Marker and a Potential Therapeutic Target for Multiple Myeloma Tumor-Initiating Cells. Journal of the National Cancer Institute. 2019 112(5):507-515.
Hao M, Barlogie B, Tricot G, [et al., including Zhan F]. Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenstrom?s Macroglobulinemia. Clinical Cancer Research. 2019 25(1):201-209.
Franqui-Machin R, Hao M, Bai H, [et al., including Zhan F]. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. The Journal of clinical investigation. 2018 128(7):2877-2893. PMID: 29863498. PMCID: PMC6026005.
Guo A, Wang Y, Chen B, [et al., including Zhan F]. The E-C coupling structure protein junctophilin-2 encodes a stress-adaptive transcription regulator. Science. 2018 362(6421):1375-1384.
Hao M, Franqui-Machin R, Xu H, [et al., including Zhan F]. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia. 2017 31(7):1648-1650. PMID: 28400617. PMCID: PMC5508075.
Xia J, Xu H, Zhang X, [et al., including Zhan F]. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 18:41-49. PMID: 28229908. PMCID: PMC5405162.
Gu Z, Xia J, Xu H, [et al., including Zhan F]. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. Journal of hematology & oncology. 2017 10(1):17. PMID: 28086949. PMCID: PMC5237262.
Huang J, Zhou Y, Thomas GS, [et al., including Zhan F]. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 21(24):5532-42. PMID: 26156395. PMCID: PMC4804624.
Gu Z, Wang H, Xia J, [et al., including Zhan F]. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer research. 2015 75(11):2211-21. PMID: 25855377. PMCID: PMC4946247.
Yang Y, Shi J, Gu Z, [et al., including Zhan F]. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer research. 2015 75(3):594-604. PMID: 25589346. PMCID: PMC4384656.
Zhan F, Zangari M, Qiu L. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics. BioMed research international. 2015 2015:384575. PMID: 26000289. PMCID: PMC4427090.
Zhou W, Yang Y, Gu Z, [et al., including Zhan F]. ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. Leukemia. 2014 28(5):1155-8. PMID: 24365790. PMCID: PMC4018236.
Yang Y, Shi J, Tolomelli G, [et al., including Zhan F]. RAR?2 expression confers myeloma stem cell features. Blood. 2013 122(8):1437-47. PMID: 23847194. PMCID: PMC3750340.
Veitonmäki N, Hansson M, Zhan F, [et al.]. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer cell. 2013 23(4):502-15. PMID: 23597564.
Zhou W, Yang Y, Xia J, [et al., including Zhan F]. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer cell. 2013 23(1):48-62. PMID: 23328480. PMCID: PMC3954609.
Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer treatment reviews. 2012 38(8):968-80. PMID: 22226939.
Zangari M, Berno T, Zhan F, [et al.]. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Seminars in thrombosis and hemostasis. 2012 38(8):768-79. PMID: 23104518.
Zangari M, Berno T, Zhan F, [et al.]. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2011 22(5):420-3. PMID: 21537162.
Zangari M, Aujay M, Zhan F, [et al.]. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. European journal of haematology. 2011 86(6):484-7. PMID: 21477075.
Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clinical lymphoma, myeloma & leukemia. 2011 11(2):228-36. PMID: 21575928.
Zangari M, Yaccoby S, Pappas L, [et al., including Zhan F]. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011 96(2):333-6. PMID: 20952514. PMCID: PMC3031705.
Cruz RD, Tricot G, Zangari M, Zhan F. Progress in myeloma stem cells. American journal of blood research. 2011 1(2):135-45. PMID: 22432075. PMCID: PMC3301427.
Wu X, Shi J, Wu Y, [et al., including Zhan F]. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer biology & therapy. 2010 10(11):1201-14. PMID: 20953137. PMCID: PMC3047108.
Zangari M, Zhan F, Tricot G. Bone and paraproteinemias. Current opinion in supportive and palliative care. 2010 4(3):195-9. PMID: 20657285.
Shi L, Wang S, Zangari M, [et al., including Zhan F]. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010 1(1):22-33. PMID: 20930946. PMCID: PMC2949973.
Chen L, Wang S, Zhou Y, [et al., including Zhan F]. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood. 2010 115(1):61-70. PMID: 19837979. PMCID: PMC2803692.
Zangari M, Tricot G, Polavaram L, [et al., including Zhan F]. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 28(1):132-5. PMID: 19901114.
Zangari M, Fink LM, Elice F, [et al., including Zhan F]. Thrombotic events in patients with cancer receiving antiangiogenesis agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 27(29):4865-73. PMID: 19704059.
van Rhee F, Szmania SM, Dillon M, [et al., including Zhan F]. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular cancer therapeutics. 2009 8(9):2616-24. PMID: 19723891. PMCID: PMC2748787.
Wang S, Tricot G, Shi L, [et al., including Zhan F]. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009 114(3):600-7. PMID: 19458357. PMCID: PMC2713470.
Wang S, Tricot G, Shi L, [et al., including Zhan F]. RARa2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009 114(3):600-607.
Xiong W, Wu X, Starnes S, [et al., including Zhan F]. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008 112(10):4235-46. PMID: 18337559. PMCID: PMC2581979.
Hsi ED, Steinle R, Balasa B, [et al., including Zhan F]. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 14(9):2775-84. PMID: 18451245. PMCID: PMC4433038.
Yaccoby S, Pennisi A, Li X, [et al., including Zhan F]. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 2008 22(2):406-13. PMID: 18046446. PMCID: PMC2771378.
Zhan F, Barlogie B, Mulligan G, [et al.]. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008 111(2):968-969.
Haessler J, Shaughnessy JD Jr, Zhan F, [et al.]. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 13(23):7073-9. PMID: 18056185.
Szmania S, Gnjatic S, Tricot G, [et al., including Zhan F]. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2007 30(8):847-54. PMID: 18049337.
Li X, Pennisi A, Zhan F, [et al.]. Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. British journal of haematology. 2007 138(6):802-11. PMID: 17760811. PMCID: PMC2748973.
Qian J, Xie J, Hong S, [et al., including Zhan F]. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007 110(5):1587-94. PMID: 17515399. PMCID: PMC1975842.
Annunziata CM, Davis RE, Demchenko Y, [et al., including Zhan F]. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer cell. 2007 12(2):115-30. PMID: 17692804. PMCID: PMC2730509.
Zhan F, Colla S, Wu X, [et al.]. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007 109(11):4995-5001. PMID: 17303695. PMCID: PMC1885527.
Colla S, Zhan F, Xiong W, [et al.]. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007 109(10):4470-7. PMID: 17255354. PMCID: PMC1885505.
Shaughnessy JD Jr, Zhan F, Burington BE, [et al.]. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 109(6):2276-84. PMID: 17105813.
Yaccoby S, Ling W, Zhan F, [et al.]. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007 109(5):2106-11. PMID: 17068150. PMCID: PMC1801040.
Zhan F, Barlogie B, Arzoumanian V, [et al.]. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 109(4):1692-700. PMID: 17023574. PMCID: PMC1794073.
Prasad HK, Zhan F, Shaugnessy J. Smoldering multiple myeloma. New England Journal of Medicine. 2007 357(10):1048.
Zhan F, Huang Y, Colla S, [et al.]. The molecular classification of multiple myeloma. Blood. 2006 108(6):2020-8. PMID: 16728703. PMCID: PMC1895543.
Hanamura I, Stewart JP, Huang Y, [et al., including Zhan F]. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006 108(5):1724-32. PMID: 16705089. PMCID: PMC1895503.
Carrasco DR, Tonon G, Huang Y, [et al., including Zhan F]. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer cell. 2006 9(4):313-25. PMID: 16616336.
Ge Y, Zhan F, Barlogie B, [et al.]. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British journal of haematology. 2006 133(1):83-92. PMID: 16512833.
Bergsagel PL, Kuehl WM, Zhan F, [et al.]. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005 106(1):296-303. PMID: 15755896. PMCID: PMC1895118.
van Rhee F, Szmania SM, Zhan F, [et al.]. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005 105(10):3939-44. PMID: 15671442. PMCID: PMC1895070.
Santin AD, Zhan F, Cane' S, [et al.]. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British journal of cancer. 2005 92(8):1561-73. PMID: 15785748. PMCID: PMC2362016.
Santin AD, Zhan F, Bignotti E, [et al.]. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005 331(2):269-91. PMID: 15629771.
Santin AD, Zhan F, Bellone S, [et al.]. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International journal of cancer. 2004 112(1):14-25. PMID: 15305371.
Santin AD, Zhan F, Bellone S, [et al.]. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. British journal of cancer. 2004 90(9):1814-24. PMID: 15208622. PMCID: PMC2409747.
Tian E, Zhan F, Walker R, [et al.]. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The New England journal of medicine. 2003 349(26):2483-94. PMID: 14695408.
Kelly T, Miao HQ, Yang Y, [et al., including Zhan F]. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer research. 2003 63(24):8749-56. PMID: 14695190.
Batchu RB, Moreno AM, Szmania S, [et al., including Zhan F]. High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. Human gene therapy. 2003 14(14):1333-45. PMID: 14503968.
Shaughnessy J, Jacobson J, Sawyer J, [et al., including Zhan F]. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 101(10):3849-56. PMID: 12531801.
Zhan F, Tian E, Bumm K, [et al.]. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003 101(3):1128-40. PMID: 12393520.
Zhan F, Hardin J, Kordsmeier B, [et al.]. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002 99(5):1745-57. PMID: 11861292.
Shaugnessy J, Gabrea A, Yi Q, [et al., including Zhan F]. Cyclin D3 at 6p21 is downregulated by recurrent Ig translocations in multiple myeloma. Blood. 2001 98(1):217-223.